Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
home:diseases:celiac [02.19.2019]
sallieq [recent research]
home:diseases:celiac [07.20.2019]
sallieq [recent research]
Line 5: Line 5:
 ====== Celiac disease ====== ====== Celiac disease ======
  
-<​relatedarticles>​ [[home:​diseases:​ibs|Irritable bowel syndrome]], [[home:​diseases:​ibd|Crohn'​s disease and ulcerative colitis]] </​article>​+<​relatedarticles>​ [[home:​diseases:​ibs|Irritable bowel syndrome]], [[home:​diseases:​ibd|Crohn'​s disease and ulcerative colitis]], [[home:​protocol:​olmesartan:​safety#​recent_research|Recent research into Safety of Olmesartan]] </​article>​
  
  
Line 31: Line 31:
 CONCLUSIONS:​ The mode of delivery and associated alterations in the development of the enteric homeostasis during the neonatal period might influence the incidence of celiac disease. ​ (({{pubmed>​long:​20478942}})) CONCLUSIONS:​ The mode of delivery and associated alterations in the development of the enteric homeostasis during the neonatal period might influence the incidence of celiac disease. ​ (({{pubmed>​long:​20478942}}))
 </​blockquote>​ </​blockquote>​
 +
 +The emerging data on viral and bacterial microbe-host interactions and their alterations in celiac disease provides a plausible mechanism linking environmental risk and disease development. (({{pubmed>​long:​30519552}}))
  
  
Line 63: Line 65:
 [[http://​science.sciencemag.org/​content/​356/​6333/​44| study in humans supports a role for infection with reovirus, a seemingly innocuous virus, in triggering the development of CeD]] [[http://​science.sciencemag.org/​content/​356/​6333/​44| study in humans supports a role for infection with reovirus, a seemingly innocuous virus, in triggering the development of CeD]]
 (({{pubmed>​long:​28386004}})) (({{pubmed>​long:​26060107}})) (({{pubmed>​long:​28386004}})) (({{pubmed>​long:​26060107}}))
 +
 +Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. ​ (({{pubmed>​long:​25023670}}))
 +
 +In 2015 I saw that 6 individuals in the USA were suing maker of Benicar. (//​presumably for bowel immunopathology caused by cytokines//​). //Somewhere else I found that 1.9 million individuals are currently taking Olmesartan Medoxomil.// ​ //6 in 1.9 million ? Seems pretty rare to me.// (//​Editor//​)
 +
 +Gluten in "​gluten-free"​ manufactured foods in Australia: a cross-sectional study. ​ (({{pubmed>​long:​30404591}})) PMID 30404591
 +
 +
 +2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. ​
 +(({{pubmed>​long:​30594690}}))
  
 {{tag>​diseases }} {{tag>​diseases }}
home/diseases/celiac.txt · Last modified: 07.20.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.